Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;25(4):641-653.
doi: 10.1007/s10198-023-01614-6. Epub 2023 Jul 11.

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma

Jean-Baptiste Trouiller  1   2 , Georgios F Nikolaidis  3 , Bérengère Macabeo  4   5 , Nicolas Meyer  6 , Laetitia Gerlier  7 , Max Schlueter  3 , Philippe Laramee  4   5
Affiliations

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma

Jean-Baptiste Trouiller et al. Eur J Health Econ. 2024 Jun.

Abstract

Objective: The objective of this study was to determine the cost-effectiveness of encorafenib with binimetinib (EncoBini) as compared to other targeted double combination therapies, namely dabrafenib with trametinib (DabraTrame) and vemurafenib with cobimetinib (VemuCobi), for the treatment of BRAF V600-mutant unresectable or metastatic melanoma (MM) from the French payer perspective.

Methods: A partitioned survival model was developed considering a lifetime horizon. The model structure simulated the clinical pathway of patients with BRAF V600-mutant MM. Clinical effectiveness and safety inputs were sourced from the COLUMBUS trial, a network meta-analysis and published literature. Costs, resource use, and the quality of life inputs were obtained from the literature and appropriate French sources.

Results: Over a lifetime horizon, EncoBini was associated, on average, with reduced costs and increased quality adjusted life years (QALYs), dominating both targeted double combination therapies. For a willingness-to-pay threshold of €90,000 per QALY, the probability of EncoBini being cost-effective against either comparator remained above 80%. The most influential model parameters were the hazard ratios for the overall survival of EncoBini vs DabraTrame and VemuCobi, the pre- and post-progression utility values, as well as treatment dosages and the relative dose intensity of all interventions.

Conclusion: EncoBini is associated with reduced costs and increased QALYs, dominating other targeted double combination therapies (DabraTrame, VemuCobi) for patients with BRAF V600-mutant MM in France. EncoBini is a highly cost-effective intervention in MM.

Keywords: BRAF; Cost-effectiveness; Economic analysis; Encorafenib; QALY; Unresectable or metastatic melanoma.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Miller, A.J., Mihm, M.C., Jr.: Melanoma. N Engl J Med. 355(1), 51–65 (2006) - DOI - PubMed
    1. Potrony, M., Badenas, C., Aguilera, P., Puig-Butille, J.A., Carrera, C., Malvehy, J., et al.: Update in genetic susceptibility in melanoma. Ann Transl Med. 3(15), 210 (2015) - PubMed - PMC
    1. Ryu, S., Youn, C., Moon, A.R., Howland, A., Armstrong, C.A., Song, P.I.: Therapeutic inhibitors against mutated BRAF and MEK for the treatment of metastatic melanoma. Chonnam Med J. 53(3), 173–177 (2017) - DOI - PubMed - PMC
    1. American Cancer Society. Cancer Facts and Figures. 2022.
    1. Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., Keilholz, U.: Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5), v126–v132 (2015) - DOI - PubMed

MeSH terms

LinkOut - more resources